中国防痨杂志 ›› 2013, Vol. 35 ›› Issue (7): 488-510.
中国防痨协会临床专业委员会
收稿日期:
2013-04-07
出版日期:
2013-07-10
发布日期:
2013-07-02
通信作者:
唐神结
E-mail:tangsj1106@sina.com
Clinic Society of Chinese Antituberculosis Association
Received:
2013-04-07
Online:
2013-07-10
Published:
2013-07-02
Contact:
TANG Shen-jie
E-mail:tangsj1106@sina.com
摘要: 近一年来,国内外在结核病临床治疗方面也取得了不少进展,许多新药物、新方案、新疗法在临床中得到了应用与验证。2012年,抗结核新药研究最令人鼓舞的事件是贝达喹啉(bedaquiline,TMC207)已被美国FDA批准上市,并可用于治疗耐多药结核病。免疫治疗及治疗性疫苗在临床结核病中的研究也取得了一定的进展。一项采用经过热处理灭活的Mycobacterium indicus pranii(MIP)及糖皮质激素联合化疗治疗结核渗出性心包炎的国际多中心随机、双盲、安慰剂对照研究值得关注。本报告介绍了肝炎治疗性疫苗V5用于治疗结核病的一项随机、双盲、安慰剂对照Ⅱb期临床研究结果。呼吸内镜介入治疗方面主要集中在评估各种方法在结核病中的治疗价值;同时较为系统地介绍了《气管支气管结核诊断和治疗指南(试行)》中介入治疗方面的内容。在结核病外科治疗方面补充了骨结核外科治疗进展,尤其是脊柱结核手术治疗的新方式及其应用。抗结核治疗新方案在耐药结核病治疗中的应用也进行了深入的研究。结核病合并HIV感染的治疗也取得了较大的进展,包括Mtb与HIV双重感染的预防性抗结核治疗、结核病治疗、抗逆转录病毒治疗、抗结核药物与抗逆转录病毒治疗药物之间相互作用、临床治疗效果、治疗不良反应,以及免疫重建炎症综合征等7个部分内容。
中国防痨协会临床专业委员会. 结核病临床诊治进展年度报告(2012年)(第二部分 结核病临床治疗)[J]. 中国防痨杂志, 2013, 35(7): 488-510.
Clinic Society of Chinese Antituberculosis Association. Annual report on clinical diagnosis and treatment progress of tuberculosis(2012)(Part 2 clinical treatment)[J]. Chinese Journal of Antituberculosis, 2013, 35(7): 488-510.
[1]Diacon AH,Donald PR,Pym A,et al.Randomized pilot trial of eight weeks of bedaquiline(TMC207)treatment for multidrug-resistant tuberculosis:long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother,2012,56(6):3271-3276.[2]Diacon AH,Dawson R,du Bois J,et al. Phase Ⅱ dose-ranging trial of the early bactericidal activity of PA-824.Antimicrob Agents Chemother,2012,56(6):3027-3031.[3]Gler MT,Skripconoka V,Sanchez-Garavito E,et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med,2012,366(23):2151-2160.[4]National Institutes of Health. Safety and efficacy trial of delamanid for 6 months in patients with multidrug resistant tuberculosis[DB/OL]. Bethesda(USA):National Institutes of Health, 2011(2012-12-04)[2013-01-16]. http://clinicaltrials.gov/show/NCT01424670.[5]Lee M,Lee J,Carroll MW,et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med,2012,367(16):1508-1518.[6]吴彪,符娟,符健,等.利奈唑胺治疗结核性脑膜炎临床疗效.现代预防医学,2012,39(17):4563-4565.[7]Cox H,Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis:a systematic review and meta-analysis. Int J Tuberc Lung Dis,2012,16(4):447-454.[8]Singla R,Caminero JA,Jaiswal A,et al.Linezolid:an effective,safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J,2012,39(4):956-962.[9]Williams K,Minkowski A,Amoabeng O,et al. Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother,2012,56(6):3114-3120.[10]Tahlan K,Wilson R,Kastrinsky DB,et al. SQ109 targets MmpL3,a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother,2012,56(4):1797-1809.[11]Ruslami R,Ganiem AR,Dian S,et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis:an open-label,randomised controlled phase 2 trial. Lancet Infect Dis,2013,13(1):27-35.[12]陈俊林,施军卫,顾德林,等.莫西沙星及利福布丁方案对初次复治涂阳肺结核超短程治疗价值.重庆医学,2012,41(28):2966-2968.[13]吴俐健,孙美秋,王笑歌. 143例含莫西沙星化疗方案治疗首次复阳肺结核临床研究.实用预防医学,2012,19(2):231-233.[14]王海宾,檀新云,康书慧,等.联用加替沙星治疗涂阳重度肺结核病的疗效分析.河北医药,2012,34(6):883-884.[15]Diacon AH,Dawson R,von Groote-Bidlingmaier F,et al. 14-day bactericidal activity of PA-824,bedaquiline,pyrazinamide,and moxifloxacin combinations:a randomised trial. Lancet, 2012, 380(9846):986-993.[16]Gupta A,Ahmad FJ,Ahmad F,et al. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One,2012,7(7):e39215.[17]Gupta A,Ahmad FJ,Ahmad F,et al. Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model. Vaccine, 2012, 30(43): 6198-6209.[18]Mayosi BM,Ntsekhe M,Bosch J,et al. Rationale and design of the Investigation of the Management of Pericarditis(IMPI)trial:a 2×2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. Am Heart J,2013,165(2):109-115.[19]Butov DA,Efremenko YV,Prihoda ND,et al. Adjunct immune therapy of first-diagnosed TB,relapsed TB,treatment-failed TB,multidrug-resistant TB and TB/HIV. Immunotherapy, 2012, 4(7): 687-695.[20]Zhang Y,Liu J,Wang Y,et al. Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Sci China Life Sci,2012,55(9):800-806.[21]Cayabyab MJ,Kashino SS,Campos-Neto A. Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA/protein heterologous prime/boost protocol. Immunology,2012,135(3):216-225.[22]Efremenko YV,Arjanova OV,Prihoda ND,et al. Clinical validation of sublingual formulations of Immunoxel(Dzherelo)as an adjuvant immunotherapy in treatment of TB patients. Immunotherapy, 2012, 4(3):273-282.[23]Lee JY,Yim JJ,Yoon BW. Adjuvant interferon-γ treatment in two cases of refractory tuberculosis of the brain.Clin Neurol Neurosurg,2012,114(6):732-734.[24]Lee HS,Lee Y,Lee SO,et al. Adalimumab treatment may replace or enhance the activity of steroids in steroid-refractory tuberculous meningitis. J Infect Chemother,2012,18(4):555-557.[25]祝斌,陶成春,金柱,等.免疫治疗在初治肺结核中的作用.临床肺科杂志,2012,17(2):271-272.[26]陈尊杰,符慧,黄钥藩.胸腺肽联合抗结核药治疗复治涂阳肺结核临床观察.实用医学杂志,2012,28(14):2437-2438.[27]卢万向.胸腺五肽联合化疗治疗糖尿病合并结核性胸膜炎临床疗效观察.中国实用医药,2012,7(5):36-37.[28]Scriba TJ,Tameris M,Smit E,et al. A phase Ⅱa trial of the new tuberculosis vaccine,MVA85A,in HIV-and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med,2012,185(7):769-778.[29]Odutola AA,Owolabi OA,Owiafe PK,et al. A new TB vaccine,MVA85A,induces durable antigen-specific responses 14 months after vaccination in African infants. Vaccine, 2012, 30(38): 5591-5594.[30]Pathan AA,Minassian AM,Sander CR,et al. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine,MVA85A,in BCG vaccinated UK adults. Vaccine, 2012, 30(38):5616-5624.[31]You Q,Jiang C,Wu Y,et al. Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein,but not an adenovirus-based vaccine,protects mice against intravenous challenge with Mycobacterium tuberculosis. Scand J Immunol,2012,75(1):77-84.[32]梁艳,吴雪琼,张俊仙,等.结核分枝杆菌Ag85A DNA疫苗抗结核作用的研究.中国防痨杂志,2012,34(3):181-183.[33]Dou J,Wang Y,Yu F,et al. Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int J Immunogenet, 2012, 39(2):183-190.[34]Zhao S,Zhao Y,Mao F,et al. Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice. PLoS One, 2012,7(2):e31908.[35]Guo XQ,Wei YM,Yu B. Recombinant Mycobacterium smegmatis expressing Hsp65-hIL-2 fusion protein and its influence on lymphocyte function in mice. Asian Pac J Trop Med, 2012, 5(5):347-351.[36]You Q,Jiang C,Kong W,et al. Attempted immunotherapy for Mycobacterium tuberculosis with viral and protein vaccines based on Ag85B-ESAT6 in a mouse model. Acta Microbiol Immunol Hung,2012,59(1):63-75.[37]Beamer GL,Cyktor J,Flaherty DK,et al. CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection. Eur J Immunol,2012,42(4):870-879.[38]Spencer AJ,Hill F,Honeycutt JD,et al. Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. PLoS One,2012,7(3):e33555.[39]You Q,Wu Y,Jiang D,et al. Immune responses induced by heterologous boosting of recombinant bacillus Calmette-Guerin with Ag85B-ESAT6 fusion protein in levamisole-based adjuvant. Immunol Invest,2012,41(4):412-428.[40]Wang C,Fu R,Chen Z,et al. Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B. Clin Dev Immunol,2012,2012:563838.[41]Liang Y,Wu X,Zhang J,et al. Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with Mycobacterium tuberculosis. FEMS Immunol Med Microbiol,2012,66(3):419-426.[42]Lin PL,Dietrich J,Tan E,et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest,2012,122(1):303-314.[43]Billeskov R,Elvang TT,Andersen PL,et al. The HyVac4 su-bunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One,2012,7(6):e39909.[44]Luo Y,Jiang W,Da Z,et al. Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule. Scand J Immunol,2012,75(3):293-300.[45]中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会. 气管支气管结核诊断和治疗指南(试行). 中华结核和呼吸杂志,2012,35(8):581-587.[46]张景熙,白冲,黄海东,等.经气管镜冷冻联合药物灌注对透壁型纵隔支气管旁淋巴结结核的治疗作用.中华结核和呼吸杂志,2011,34(12):898-903.[47]倪彩云,刘霞,马静,等. 支气管镜下冷冻治疗儿童肉芽及瘢痕组织导致的下气道狭窄及阻塞22例.中华儿科杂志,2012,50(1):45-49.[48]Iaitskiǐ NA,Gerasin VA,Gerasin AV,et al. The role of endoscopic methods in treatment of tracheal cicatricial stenoses. Vestn Khir Im I I Grek,2012,171(3):11-15.[49]陈愉,伍惠仪,李时悦. 局部注射曲安奈德结合常规介入方法治疗难治性良性中央气道狭窄疗效及安全性的初步探讨. 中华结核和呼吸杂志,2012,35(6):415-418.[50]Garg M,Gogia P,Manoria P,et al. Bronchoscopic management of benign bronchial stenosis by electrocautery and balloon dilatation. Indian J Chest Dis Allied Sci,2012,54(1):41-43.[51]崔佳,张杰,王娟,等. 局部应用丝裂霉素C对良性瘢痕增生性气道狭窄抑制作用的初步研究. 中华结核和呼吸杂志,2012,35(12):901-906.[52]Jin F,Mu D,Xie Y,et al. Application of bronchoscopic argon plasma coagulation in the treatment of tumorous endobronchial tuberculosis:historical controlled trial. J Thorac Cardiovasc Surg,2013,145(6):1650-1653.[53]Au JT,Carson J,Monette S,et al. Spray cryotherapy is effective for bronchoscopic,endoscopic and open ablation of thoracic tissues. Interact Cardiovasc Thorac Surg,2012,15(4):580-584.[54]姚向阳,王叙嫄,伍定辉,等.球囊扩张术治疗结核性支气管瘢痕狭窄的临床疗效分析.中国防痨杂志,2012,34(7):472-474.[55]Verma A,Um SW,Koh WJ,et al. Long-term tolerance of airway silicone stent in patients with post-tuberculosis tracheobronchial stenosis. ASAIO J,2012,58(5):530-534.[56]Verma A,Park HY,Lim SY,et al.Posttuberculosis tracheobronchial stenosis:use of CT to optimize the time of silicone stent removal. Radiology,2012,263(2):562-568.[57]魏喜玲,梁占伟,李志惠,等.经气管镜微创介入治疗146例支气管结核疗效分析.临床肺科杂志,2012,17(5):841-843.[58]朱春梅.冷冻及球囊扩张等多方式介入治疗结核性气管狭窄观察. 临床肺科杂志,2012,17(4):667-668.[59]陶红艳,万毅新,魏海东,等.支气管镜下介入治疗支气管结核气道阻塞82例临床疗效分析.中国防痨杂志,2012,34(1):29-31.[60]宫希涛,刘玉峰,田红. 经支气管镜注药辅助治疗耐多药肺结核临床研究.中国内镜杂志,2012,18(6):647-649.[61]许优,王勃,蔡署波,等. C型臂引导下经支气管镜介入治疗空洞型肺结核30例疗效观察.陕西医学杂志,2012,41(5):538-540.[62]厉银平,刘桂霞,彭清臻,等.内科胸腔镜结合尿激酶治疗结核性包裹性胸腔积液的临床应用.临床肺科杂志,2012,17(9):1621-1623.[63]金明华,王伟,王传庆,等.电视胸腔镜脓胸廓清术治疗结核性脓胸.中国微创外科杂志,2012,12(6):524-526.[64]Lim AL,Kim CH,Hwang YI. Bronchoscopic ethanolamine injection therapy in patients with persistent air leak from chest tube drainage.Tuberc Respir Dis(Seoul),2012,72(5):441-447.[65]Nemati A,Safavi E,GhasemiEsfe M,et al.Fistula formation between the right and left main bronchus caused by endobronchial tuberculosis. Am J Med Sci,2012,343(4):330-331.[66]Cummings I,O’Grady J,Pai V,et al. Surgery and tuberculosis. Curr Opin Pulm Med,2012,18(3):241-245.[67]Odell JA. The history of surgery for pulmonary tuberculosis. Thorac Surg Clin,2012, 22(3):257-269.[68]丁嘉安,谢冬.肺结核外科治疗新进展.结核病与肺部健康杂志,2012,1(1):55-59.[69]Man MA,Nicolau D. Surgical treatment to increase the success rate of multidrug-resistant tuberculosis. Eur J Cardiothorac Surg,2012,42(1):e9-12.[70]Iddriss A,Padayatchi N,Reddy D,et al. Pulmonary resection for extensively drug resistant tuberculosis in Kwazulu-Natal,South Africa. Ann Thorac Surg,2012,94(2):381-386.[71]Kempker RR,Vashakidze S,Solomonia N,et al. Surgical treatment of drug-resistant tuberculosis.Lancet Infect Dis,2012,12(2):157-166.[72]Byun CS,Chung KY,Narm KS,et al. Early and long-term outcomes of pneumonectomy for treating sequelae of pulmonary tuberculosis. Korean J Thorac Cardiovasc Surg,2012,45(2):110-115.[73]Mordant P,Badia A,Le Pimpec-Barthes F,et al. Thoracic surgery in tuberculosis and non-tuberculous mycobacterial diseases. Rev Pneumol Clin,2012,68(2):77-83.[74]宋言峥,王旭,卢水华,等.“LTB-S”分类法与耐多药肺结核手术适应证探讨.中国防痨杂志,2012,34(4):245-247.[75]Papiashvili M,Barmd I,Sasson L,et al. Pulmonary resection for multidrug-resistant tuberculosis:the Israeli experience(1998-2011).Isr Med Assoc J,2012,14(12):733-736.[76]Bai L,Hong Z,Gong C,et al. Surgical treatment efficacy in 172 cases of tuberculosis-destroyed lungs. Eur J Cardiothorac Surg,2012,41(2):335-340.[77]Bagheri R,Haghi SZ,Rajabi MT,et al. Outcomes following surgery for complicated tuberculosis:analysis of 108 patients. Thorac Cardiovasc Surg,2013,61(2):154-158.[78]吴纪峰,王晓彬,刘佳坤,等.58例结核性毁损肺的外科治疗.临床肺科杂志,2012,17(5):831-833.[79]吴纪峰,冯光,苏月巧,等.结核性毁损肺合并对侧不稳定肺结核的手术指征研究.临床肺科杂志,2012,17(11):2019-2020.[80]Ragusa M,Vannucci J,Cagini L,et al. Left main bronchus resection and reconstruction. A single institution experience. J Cardiothorac Surg,2012,7:29.[81]Takahashi S,Hata Y,Sasamoto S,et al. Recovery of lung perfusion after sleeve resection for tuberculous bronchial stenosis.Ann Thorac Surg,2012,93(6):2041-2043.[82]Ikeda M,Sonobe M,Date H. Resection of bronchial stricture and destroyed lung after pulmonary tuberculosis. Interact Cardiovasc Thorac Surg,2012,14(5):652-654.[83]Yen YT,Wu MH,Lai WW,et al. The role of video-assisted thoracoscopic surgery in therapeutic lung resection for pulmonary tuberculosis. Ann Thorac Surg,2013,95(1):257-263.[84]Tanaka S,Aoki M,Nakanishi T,et al. Retrospective case series analysing the clinical data and treatment options of patients with a tubercular abscess of the chest wall. Interact Cardiovasc Thorac Surg,2012,14(3):249-252.[85]Deng B,Tan QY,Wang RW,et al. Surgical strategy for tubercular abscess in the chest wall:experience of 120 cases. Eur J Cardiothorac Surg,2012,41(6):1349-1352.[86]Keum DY,Kim JB,Park CK. Surgical treatment of a tuberculous abscess of the chest wall. Korean J Thorac Cardiovasc Surg,2012,45(3):177-182.[87]钱勇,杨继承,袁跃西.120例胸壁结核外科治疗体会.中国现代手术学杂志,2011,15(5):364-365.[88]许军利,郭皖营,陈其亮,等.胸壁结核468例手术治疗体会.中国临床医生,2012,40(7):55-57.[89]李鹏程,郑梦利,邱亚斌,等.皮瓣联合真皮瓣填充修复胸壁结核性溃疡创面八例.中华烧伤杂志,2012,28(1):55-56.[90]Zhang N,Xu QZ,Fu XN,et al. Use of a pedicled omental flap in the treatment of chest wall tuberculosis. Ann Thorac Surg,2012,93(3):1010-1012.[91]宋言峥,王旭,刘保池,等. 结核病灶内定点清除术的临床应用.中华结核和呼吸杂志,2012,35(5):380-381.[92]Marks DJ,Fisk MD,Koo CY,et al. Thoracic empyema:a 12-year study from a UK tertiary cardiothoracic referral centre. PLoS One,2012,7(1):30074.[93]Yang HC,Han J,Lee S,et al. Evaluation of decortication in patients with chronic tuberculous empyema by three-dimensional computed tomography densitometry. Thorac Cardiovasc Surg, 2013,61(2):159-166.[94]Bobocea AC,Paleru C,Lovin C,et al. Videomediastinoscopic transcervical approach of postpneumonectomy left main bronchial fistula. Pneumologia,2012,61(1):44-47.[95]Ahn HY,Cho JS,Kim YD,et al. Intrathoracic muscular transposition in chronic tuberculous empyema. Thorac Cardiovasc Surg,2013,61(2):167-171.[96]Dalar L,Kosar F,Eryuksel E,et al. Endobronchial watanabe spigot embolisation in the treatment of bronchopleural fistula due to tuberculous empyema in intensive care unit. Ann Thorac Cardiovasc Surg,2013,19(2):140-143.[97]曹烨,宋言峥,李垒,等.经典病灶清除手术治疗复杂复合性脊柱结核104例临床分析.中国防痨杂志,2012,34(7):437-440.[98]Wang H,Li C,Wang J,et al. Characteristics of patients with spinal tuberculosis:seven-year experience of a teaching hospital in Southwest China. Int Orthop,2012,36(7):1429-1434.[99]Mak KC,Cheung KM. Surgical treatment of acute TB spondylitis:indications and outcomes. Eur Spine J,2012 Aug 16. [Epub ahead of print][100]Pola E,Rossi B,Nasto LA,et al.Surgical treatment of tuberculous spondylodiscitis. Eur Rev Med Pharmacol Sci,2012,Suppl 2:79-85.[101]Zhang HQ,Lin MZ,Ge L,et al. Surgical management by one-stage posterior transforaminal lumbar debridement,interbody fusion,and posterior instrumentation for lumbo-sacral tuberculosis in the aged. Arch Orthop Trauma Surg,2012,132(12):1677-1683.[102]Wang XB,Li J,Lü GH,et al. Single-stage posterior instrumentation and anterior debridement for active tuberculosis of the thoracic and lumbar spine with kyphotic deformity. Int Orthop,2012,36(2):373-380.[103]Song JF,Jing ZZ,Chen B,et al. One-stage anterolateral surgical treatment for lumbosacral segment tuberculosis. Int Orthop,2012,36(2):339-344.[104]Zhang HQ,Li JS,Guo CF,et al. Two-stage surgical management using posterior instrumentation,anterior debridement and allografting for tuberculosis of the lower lumbar spine in children of elementary school age:minimum 3-year follow-up of 14 patients. Arch Orthop Trauma Surg,2012,132(9):1273-1279.[105]El-Sharkawi MM,Said GZ. Instrumented circumferential fusion for tuberculosis of the dorso-lumbar spine. A single or double stage procedure? Int Orthop,2012,36(2):315-324.[106]Wang Z,Yuan H,Geng G,et al. Posterior mono-segmental fixation,combined with anterior debridement and strut graft,for treatment of the mono-segmental lumbar spine tuberculosis. Int Orthop,2012,36(2):325-329.[107]Zhang H,Huang S,Guo H,et al. A clinical study of internal fixation,debridement and interbody thoracic fusion to treat horacic tuberculosis via posterior approach only. Int Orthop,2012,36(2):293-298.[108]Shi JD,Wang ZL,Geng GQ,et al. Intervertebral focal surgery for the treatment of non-contiguous multifocal spinal tuber-culosis. Int Orthop,2012,36(7):1423-1427.[109]Issack PS,Boachie-Adjei O. Surgical correction of kyphotic deformity in spinal tuberculosis. Int Orthop,2012,6(2):353-357.[110]Pu X,Zhou Q,He Q,et al. A posterior versus anterior surgical approach in combination with debridement,interbody autografting and instrumentation for thoracic and lumbar tuberculosis. Int Orthop,2012,36(2):307-313.[111]张宏其,陈筱,郭虎兵,等.单纯后路病灶清除椎体间植骨融合内固定治疗脊柱结核的适应证及疗效评价.中国矫形外科杂志,2012,20(3):196-199.[112]Boachie-Adjei O,Papadopoulos EC,Pellisé F,et al. Late treatment of tuberculosis-associated kyphosis:literature review and experience from a SRS-GOP site. Eur Spine J,2012 May 25. [Epub ahead of print][113]Liu Y,Chen Y,Yang L,et al. The surgical treatment and related management for post-tubercular kyphotic deformity of the cervical spine or the cervico-thoracic spine. Int Orthop,2012,36(2):367-372.[114]Kapoor S,Kapoor S,Agrawal M,et al. Thoracoscopic decompression in Pott’s spine and its long-term follow-up. Int Orthop,2012,36(2):331-337.[115]Büyükbebeci O,Sekiner I,Karsl B,et al. Retroperitoneoscopic drainage of complicated psoas abscesses in patients with tuberculous lumbar spondylitis. Eur Spine J,2012,21(3):470-473.[116]Mehrotra A,Das KK,Nair AP,et al. Pediatric cranio-vertebral junction tuberculosis:management and outcome. Childs Nerv Syst,2013,29(5):809-814.[117]Deshpande SS,Mehta R,Yagnik M,et al. Short term analysis of healed post-tubercular kyphosis in younger children based on principles of congenital kyphosis. Indian J Orthop,2012,46(2):179-185.[118]Moon MS,Kim SS,Lee BJ,et al. Spinal tuberculosis in children:retrospective analysis of 124 patients. Indian J Orthop,2012,46(2):150-158.[119]Eisen S,Honywood L,Shingadia D,et al. Spinal tuberculosis in children. Arch Dis Child,2012,97(8):724-729.[120]Li L,Zhang Z,Luo F,et al.Management of drug-resistant spinal tuberculosis with a combination of surgery and individualised chemotherapy:a retrospective analysis of thirty-five patients.Int Orthop,2012,36(2):277-283.[121]Lin J,Zhou H,Zhang N,et al. Effects of the implantation of Ommaya reservoir in children with tuberculous meningitis hydrocephalus:a preliminary study. Childs Nerv Syst. 2012,28(7):1003-1008.[122]Clemente Morgado T,Kinsky M,Carrara H,et al. Prognostic value of computed tomography-evident cerebral infarcts in adult patients with tuberculous meningitis and hydrocephalus treated with an external ventricular drain. World Neurosurg,2012 Oct 3. [Epub ahead of print][123]Field SK,Fisher D,Jarand JM,et al. New treatment options for multidrug-resistant tuberculosis.Ther Adv Respir Dis,2012,6(5):255-268.[124]Migliori GB,Centis R,D’Ambrosio L,et al. Totally drug-resistant and extremely drug-resistant tuberculosis:the same disease? Clin Infect Dis,2012,54(9):1379-1380.[125]Rey-Jurado E,Tudó G,Martínez JA,et al. Synergistic effect of two combinations of antituberculous drugs against Mycobacterium tuberculosis. Tuberculosis(Edinb),2012,92(3):260-263.[126]Jo KW,Ji W,Hong Y,et al.The efficacy of rifabutin for rifabutin-susceptible,multidrug-resistant tuberculosis.Respir Med,2013,107(2):292-297.[127]刘朋冲,李志惠,赵杰,等.含利福布汀联用方案治疗耐多药肺结核的临床研究.河北医药,2012,34(11):1645-1646.[128]耿书军,刘建玲,宋韬,等.莫西沙星对老年耐多药肺结核病的临床观察.临床肺科杂志,2012,17(6):1068-1070.[129]吴树才,高官聚,耿书军,等.含莫西沙星方案与含左氧氟沙星方案对耐多药肺结核病的观察.河北医药,2012,34(3):330-332.[130]王怀冲,徐颖颖,张相彩,等.联合氯法齐明方案治疗耐多药肺结核的临床研究.中国临床药理学与治疗学,2012,17(11):1268-1271.[131]De Lorenzo S,Alffenaar JW,Sotgiu G,et al.Efficacy and safety of meropenem-clavunate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J,2013,41(6):1386-1392.[132]Sotgiu G,Centis R,D’Ambrosio L,et al. Efficacy,safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB:systematic review and meta-analysis. Eur Respir J,2012,40(6):1430-1442.[133]Floyd K,Hutubessy R,Kliiman K,et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J,2012,40(1):133-142.[134]Winston CA,Mitruka K. Treatment duration for patients with drug-resistant tuberculosis,United States.Emerg Infect Dis,2012,18(7):1201-1202.[135]Laniado-Laborín R,Estrada-Guzman J,Perez H,et al. Treatment of multidrug-resistant tuberculosis in a high-prevalence region through a binational consortium. Int J Tuberc Lung Dis,2012,16(5):610-611.[136]Kakchapati S,Gyawali BN,Jha RK,et al.Treatment outcome of multidrug-resistant Mycobacterium tuberculosis in Nepal. Asia Pac J Public Health,2012,24(4):631-640.[137]Satti H,McLaughlin MM,Hedt-Gauthier B,et al. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLoS One,2012,7(10):e46943.[138]Shenoi SV,Brooks RP,Barbour R,et al. Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One,2012,7(3):e31786.[139]Cavanaugh JS,Kazennyy BY,Nguyen ML,et al.Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel,Russia,2002-2005. Int J Tuberc Lung Dis,2012,16(8):1069-1074.[140]Kurbatova EV,Taylor A,Gammino VM,et al.Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis(Edinb), 2012,92(5):397-403.[141]Gler MT,Podewils LJ,Munez N,et al. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis,2012,16(7):955-960.[142]Blndal K,Viiklepp P,Gumundsson LJ,et al. Predictors of recurrence of multidrug-resistant and extensively drug-resis-tant tuberculosis. Int J Tuberc Lung Dis,2012,16(9):1228-1233.[143]Lee J,Lim HJ,Cho YJ,et al. Recurrence after successful treatment among patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis,2011,15(10):1331-1333.[144]Toczek A,Cox H,du Cros P,et al. Strategies for reducing treatment default in drug-resistant tuberculosis:systematic review and meta-analysis. Int J Tuberc Lung Dis,2013,17(3):299-307.[145]Nagaraja C,Shashibhushan BL,Asif M,et al. Pattern of drug-resistance and treatment outcome in multidrug-resistant pulmonary tuberculosis. Indian J Chest Dis Allied Sci,2012,54(1):23-26.[146]Skripconoka V,Danilovits M,Pehme L,et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J,2013,41(6):1393-1400.[147]World Health Orgnization. Global tuberculosis report 2012[DB/OL]. Geneva:World Health Orgnization,2012[2013-01-15]. http://www.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf.[148]Janbaz,KH,Qadir MI,Ahmad B,et al. Tuberculosis:burning issues:multidrug resistance and HIV-coinfection. Crit Rev Microbiol,2012,38(4):267-275.[149]Person,AK,Sterling TR. Treatment of latent tuberculosis infection in HIV:shorter or longer? Curr HIV/AIDS Rep,2012,9(3):259-266.[150]World Health Orgnization. WHO policy on collaborative TB/HIV activities Guidelines for national programmes and other stakeholders[DB/OL]. Geneva:World Health Orgnization,2012 [2013-01-15]. http://whqlibdoc.who.int/publications/2012/9789241503006_eng.pdf.[151]Ahmad Khan F,Minion J,Al-Motairi A,et al. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis,2012,55(8):1154-1163.[152]Bliven-Sizemore EE,Johnson JL,et al. Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment. Int J Tuberc Lung Dis,2012,16(4):473-479.[153]Kumar A,Kumar AM,Gupta D,et al. Global guidelines for treatment of tuberculosis among persons living with HIV:unresolved issues. Int J Tuberc Lung Dis,2012,16(5):573-578.[154]李玲,姚嵩,陈静. 安徽省192例HIV阳性结核病患者的治疗转归分析. 中国防痨杂志,2012,34(1):15-18.[155]Sinha S,Shekhar RC,Singh G,et al. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis,2012,12:168.[156]Curran A,Falcó V,Pahissa A,et al. Management of tuberculosis in HIV-infected patients. AIDS Rev,2012,14(4):231-246.[157]Ramkissoon S,Mwambi HG,Matthews AP. Modelling HIV and MTB co-infection including combined treatment strategies. PLoS One,2012,7(11):e49492.[158]Takuva S,Westreich D,Menezes CN,et al. Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses. Int J Tuberc Lung Dis,2012,16(10):1358-1364.[159]Manosuthi W,Mankatitham W,Lueangniyomkul A,et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients:results from the TIME study. J Acquir Immune Defic Syndr,2012,60(4):377-383.[160]Nafrialdi,Nugroho AW,Yunihastuti E,et al. Influence of ri-fampicin on nevirapine plasma concentration in HIV-TB coinfected patients. Acta Med Indones,2012,44(2):135-139.[161]Decloedt EH,Maartens G,Smith P,et al. The safety,effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PLoS One,2012,7(3):e32173.[162]Oudijk JM,McIlleron H,Mulenga V,et al. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. AIDS,2012,26(12):1523-1528.[163]Zhang C,McIlleron H,Ren Y,et al. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. Antivir Ther,2012,17(1):25-33.[164]Avihingsanon A,van der L J,Singphore U,et al.Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients:a pilot study. AIDS Res Hum Retroviruses,2012,28(10):1170-1176.[165]Shaweno D,Worku A. Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia:a retrospective cohort study. BMC Res Notes,2012,5:682.[166]Ifebunandu NA,Ukwaja KN,Obi SN. Treatment outcome of HIV-associated tuberculosis in a resource-poor setting. Trop Doct,2012,42(2):74-76.[167]Nansera D,Bajunirwe F,Elyanu P. Mortality and loss to follow-up among tuberculosis and HIV co-infected patients in rural southwestern Uganda. Int J Tuberc Lung Dis,2012,16(10):1371-1376.[168]Manosuthi W,Kawkitinarong K,Suwanpimolkul G,et al. Clinical characteristics and treatment outcomes among patients with tuberculosis in Bangkok and Nonthaburi,Thailand. Southeast Asian J Trop Med Public Health,2012,43(6):1426-1436.[169]Pefura Yone EW,Kuaban C,Kengne AP.HIV testing,HIV status and outcomes of treatment for tuberculosis in a major diagnosis and treatment centre in Yaounde,Cameroon:a re-trospective cohort study. BMC Infect Dis,2012,12:190.[170]Mugusi SF,Ngaimisi E,Janabi MY,et al. Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam,Tanzania. Antivir Ther,2012,17(2):265-274.[171]McGreevy J,Jean Juste MA,Severe P,et al. Outcomes of HIV-infected patients treated for recurrent tuberculosis with the standard retreatment regimen.Int J Tuberc Lung Dis,2012,16(6):841-845.[172]Gandhi NR,Andrews JR,Brust JC,et al. Risk factors for mortality among MDR-and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis,2012,16(1):90-97.[173]Palacios E,Franke M,Muoz M,et al. HIV-positive patients treated for multidrug-resistant tuberculosis:clinical outcomes in the HAART era.Int J Tuberc Lung Dis,2012,16(3):348-354.[174]Brust JC,Shah NS,Scott M,et al. Integrated,home-based treatment for MDR-TB and HIV in rural South Africa:an alternate model of care. Int J Tuberc Lung Dis,2012,16(8):998-1004.[175]Isaakidis P,Varghese B,Mansoor H,et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretro-viral and second line anti-TB treatment in Mumbai,India. PLoS One,2012,7(7):e40781.[176]Sagwa E,Mantel-Teeuwisse AK,Ruswa N,et al. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. South Med Rev,2012,5(1):6-13.[177]Schutz C,Ismail Z,Proxenos CJ,et al. Burden of antituberculosis and antiretroviral drug-induced liver injury at a secon-dary hospital in South Africa. S Afr Med J,2012,102(6):506-511.[178]Mugusi S,Ngaimisi E,Janabi M,et al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.PLoS One,2012,7(7):e40180.[179]Kumarasamy N,Venkatesh KK,Vignesh R,et al.Clinical outcomes among HIV/tuberculosis-coinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India. J Int Assoc Provid AIDS Care,2013,12(1):28-31.[180]Limmahakhun S,Chaiwarith R,Nuntachit N,et al.Treatment outcomes of patients co-infected with tuberculosis and HIV at Chiang Mai University Hospital,Thailand. Int J STD AIDS,2012,23(6):414-418.[181]Worodria W,Menten J,Massinga-Loembe M,et al. Clinical spectrum,risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection. Antivir Ther,2012,17(5):841-848.[182]Conesa-Botella A,Meintjes G,Coussens AK,et al.Corticosteroid therapy,vitamin D status,and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome. Clin Infect Dis,2012,55(7):1004-1011.[183]Price P,Haddow LJ,Affandi J,et al. Short communication:plasma levels of vitamin D in HIV patients initiating antiretroviral therapy do not predict immune restoration disease associated with Mycobacterium tuberculosis. AIDS Res Hum Retroviruses,2012,28(10):1216-1219. |
[1] | 马廷龙, 韩毅, 程序, 刘志东. 超声抗结核药品电导入联合化疗对胸壁结核的疗效观察[J]. 中国防痨杂志, 2020, 42(9): 968-972. |
[2] | 首都医科大学附属北京胸科医院 中国防痨协会非结核分枝杆菌分会 《中国防痨杂志》编辑委员会. 非结核分枝杆菌病治疗药品超说明书用法专家共识[J]. 中国防痨杂志, 2020, 42(8): 769-787. |
[3] | 盛杰, 朱洋, 地里下提·阿不力孜, 唐伟, 古甫丁, 宋兴华. 表型与分子药物敏感性试验对术后耐药骨关节结核患者化疗的指导与效果分析[J]. 中国防痨杂志, 2020, 42(8): 838-844. |
[4] | 王倪, 张慧, 张铁娟, 陈彬, 雷娟, 孙苗苗, 黄飞. 使用电子药盒辅助肺结核患者服药管理的实施情况分析[J]. 中国防痨杂志, 2020, 42(7): 682-686. |
[5] | 谢莉, 高静韬, 马丽萍, 张立群, 孔忠顺, 吴晓光, 刘荣梅, 陈红梅, 宋艳华, 李雪莲, 黄麦玲, 李强, 吕子征, 刘宇红, 高孟秋. 含贝达喹啉方案治疗耐多药肺结核对患者心电图QT间期的影响[J]. 中国防痨杂志, 2020, 42(7): 687-694. |
[6] | 赵本南, 刘大凤, 刘亚玲, 杨铭, 兰丽娟, 杜清. 含丙硫异烟胺和对氨基水杨酸方案治疗耐多药结核病患者致甲状腺功能减退症的临床分析[J]. 中国防痨杂志, 2020, 42(5): 465-471. |
[7] | 邱磊,张少言,郭晓燕,付际游,田黎明,张惠勇,鹿振辉. 化疗方案加芩部丹片治疗复治涂阳肺结核患者的临床价值[J]. 中国防痨杂志, 2020, 42(2): 108-114. |
[8] | 王雪迪,江锋,代倩兰,王京,王冬梅. 中西医联合与单纯西医治疗结核病所致药物性肝损伤的对比分析(2000—2019年文献复习)[J]. 中国防痨杂志, 2020, 42(2): 126-132. |
[9] | 应若嫣, 黄晓辰, 王洁, 刘一典, 沙巍, 杨华. 耐药MTB分离株对不同组合抗结核药品体外药物敏感性试验的结果分析[J]. 中国防痨杂志, 2020, 42(11): 1183-1182. |
[10] | 刘二勇, 周林, 薛晓, 刘春法, 白丽琼, 陆伟, 张天华, 成诗明. 利福平胶囊(Ⅱ)对肺结核治疗效果及安全性研究[J]. 中国防痨杂志, 2020, 42(10): 1092-1099. |
[11] | 李婷婷, 刘欢庆, 杜巧盈. 中药治疗肺结核的用药规律及作用机制预测[J]. 中国防痨杂志, 2020, 42(10): 1115-1120. |
[12] | 刘一典,桂徐蔚,申晓娜,于媛媛,姚岚,楼海,沙巍,肖和平. 2019年《ATS/CDC/ERS/IDSA临床实践指南:耐药结核病治疗》解读及与我国《耐药结核病化学治疗指南(2019年)》对比[J]. 中国防痨杂志, 2020, 42(1): 12-16. |
[13] | 王嘉雯,黄珊珊,刘恺懿,梁鸿迪,冯慧莹,周芳静,梁安棋,陈亮,周琳. 对结核病患者实施移动通信直接面视下短程督导化疗的效果评价[J]. 中国防痨杂志, 2019, 41(9): 946-950. |
[14] | 李雪,姜世闻,胡冬梅,徐彩红,刘小秋. 电子药盒和手机微信APP的应用对肺结核患者服药依从性的效果评价[J]. 中国防痨杂志, 2019, 41(9): 957-961. |
[15] | 张会军,鲁增辉,谭淦文,朱昌生. 耐药脊柱结核术后并发窦道患者实施个体化治疗的临床效果(附24例短期疗效分析)[J]. 中国防痨杂志, 2019, 41(7): 759-764. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||